This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Third look: Discussing the recent label expansion of TEPEZZA (teprotumumab-trbw) for patients with TED, regardless of disease activity or duration.

Ticker(s): AMGN

Who's the expert?

  • Cornea, Cataract and Refractive surgery specialist
  •  Served as Clinic Chief at the Stanford University Department of Ophthalmology and Director of Refractive Surgery at the Stanford University South Bay Eye Laser Center. 
  • Recipient ofmultiple honors including selected as a recipient of the Thomas D. Heed & Ruth Byers Heed Ophthalmic Foundation fellowship awarded to a select group of the nation's top
    Ophthalmologists. 
  • Has also been selected as US News & World Report Tpp Doctors, America's Top Ophthalmologists, and Top Ophthalmologists -Leading Physicians of the
    World by the International Association of Healthcare Professionals. 
  • Has over 130 publications, book chapters, national and international lectures, and courses. 
  • Is a early technology adopter and has interests include cataract surgery, premium
    intraocular lenses, glaucoma, macular degeneration, geographic atrophy, dry eye, and
    diabetic retinopathy.

Interview Goal
.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.